--- title: "Alumis | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.741 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286464058.md" datetime: "2026-05-14T20:31:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286464058.md) - [en](https://longbridge.com/en/news/286464058.md) - [zh-HK](https://longbridge.com/zh-HK/news/286464058.md) --- # Alumis | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 1.741 M Revenue: As of FY2026 Q1, the actual value is USD 1.741 M, missing the estimate of USD 2.493 M. EPS: As of FY2026 Q1, the actual value is USD -0.74, beating the estimate of USD -0.77. EBIT: As of FY2026 Q1, the actual value is USD -103.76 M. Alumis Inc. operates as a single reportable segment focused on researching and developing medicines for autoimmune disorders. #### Revenue - **Total Revenue**: $1.741 million for the three months ended March 31, 2026, a decrease from $17.389 million for the same period in 2025. - **License Revenue**: $0 for the three months ended March 31, 2026, compared to $17.389 million in 2025. - **Collaboration Revenue**: $1.741 million for the three months ended March 31, 2026, compared to $0 in 2025. #### Operating Expenses - **Total Operating Expenses**: Decreased by -$18.767 million (or -16%) to $100.150 million for the three months ended March 31, 2026, from $118.917 million for the same period in 2025. - **Research and Development (R&D) Expenses**: Decreased by -$15.082 million (or -16%) to $81.540 million for the three months ended March 31, 2026, from $96.622 million for the same period in 2025. - **External R&D Costs**: Totaled $50.102 million in 2026, down from $73.771 million in 2025. - CROs, CMOs, and clinical trials: $40.928 million (2026) vs. $65.072 million (2025). - Professional consulting services: $6.804 million (2026) vs. $6.403 million (2025). - Other R&D costs: $2.370 million (2026) vs. $2.296 million (2025). - **Internal R&D Costs**: Totaled $31.438 million in 2026, up from $22.851 million in 2025. - Personnel-related costs: $26.065 million (2026) vs. $17.659 million (2025). - Facilities and overhead costs: $5.373 million (2026) vs. $5.192 million (2025). - **External Costs by Program**: - Envu: $43.156 million (2026) vs. $66.492 million (2025). - A-005: $0.846 million (2026) vs. $3.616 million (2025). - Lonigutamab: $0.232 million (2026) vs. $0 (2025). - Other programs and R&D activities: $5.868 million (2026) vs. $3.663 million (2025). - **General and Administrative (G&A) Expenses**: Decreased by -$3.685 million (or -17%) to $18.610 million for the three months ended March 31, 2026, from $22.295 million for the same period in 2025. - Personnel-related expenses: $10.6 million (2026) vs. $7.4 million (2025). - Professional consulting services and other expenses: $7.5 million (2026) vs. $13.9 million (2025). #### Other Financial Metrics - **Net Loss**: -$93.053 million for the three months ended March 31, 2026, compared to -$98.963 million for the same period in 2025. - **Accumulated Deficit**: -$994.9 million as of March 31, 2026. - **Interest Income**: $5.349 million for the three months ended March 31, 2026, up from $2.609 million in 2025. - **Other Income (Expenses), Net**: $0.007 million for the three months ended March 31, 2026, compared to -$0.044 million in 2025. - **Stock-based Compensation Expense**: $12.339 million (2026) vs. $6.995 million (2025). #### Cash Flow - **Net cash used in operating activities**: -$87.082 million for the three months ended March 31, 2026, compared to -$80.355 million for the same period in 2025. - **Net cash (used in) provided by investing activities**: -$285.686 million for the three months ended March 31, 2026, compared to $39.428 million for the same period in 2025. - **Net cash provided by financing activities**: $346.988 million for the three months ended March 31, 2026, compared to $0 for the same period in 2025, primarily from a public offering of common stock. - **Cash, Cash Equivalents, and Marketable Securities**: $569.5 million as of March 31, 2026. #### Future Outlook and Strategy Alumis Inc. plans to submit a New Drug Application (NDA) for envu in moderate-to-severe plaque psoriasis in the second half of 2026 and anticipates reporting topline results from the Phase 2 clinical trial for envu in systemic lupus erythematosus (SLE) in the third quarter of 2026. The company is exploring strategic alternatives for its lonigutamab program following a review in May 2026. Alumis Inc. projects that its current cash, cash equivalents, and marketable securities will cover operating and capital needs for at least 12 months from the financial statements’ issuance date. ### Related Stocks - [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md) ## Related News & Research - [Alumis' Meteoric Rise To $20 From $5 In Just 60 Days On Plaque Psoriasis Trial Results](https://longbridge.com/en/news/272520322.md) - [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md) - [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md) - [Sangoma Announces Third Quarter Fiscal 2026 Results | SANG Stock News](https://longbridge.com/en/news/286317217.md) - [Vulnerability Exploitation Top Breach Entry Point, 2026 Industry-Wide DBIR Finds | VZ Stock News](https://longbridge.com/en/news/286918426.md)